Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ALISERTIB: 84 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
84
Total FAERS Reports
11 (13.1%)
Deaths Reported
13
Hospitalizations
84
As Primary/Secondary Suspect
1
Life-Threatening
1
Disabilities

First Report: 20121107 · Latest Report: 20170518

What Are the Most Common ALISERTIB Side Effects?

#1 Most Reported
Neutropenia
16 reports (19.0%)
#2 Most Reported
Dehydration
12 reports (14.3%)
#3 Most Reported
Toxicity to various agents
10 reports (11.9%)

All ALISERTIB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Neutropenia 16 19.1% 2 1
Dehydration 12 14.3% 1 4
Hyponatraemia 10 11.9% 0 2
Malignant neoplasm progression 10 11.9% 1 0
Toxicity to various agents 10 11.9% 0 0
Anaemia 9 10.7% 3 2
Leukopenia 9 10.7% 0 1
Lymphopenia 9 10.7% 0 2
Mucosal inflammation 9 10.7% 0 2
Febrile neutropenia 8 9.5% 1 2
Fatigue 7 8.3% 2 3
Vomiting 7 8.3% 1 1
Diarrhoea 6 7.1% 1 1
Thrombocytopenia 6 7.1% 2 1
Drug ineffective 5 6.0% 0 0
Dyspnoea 5 6.0% 0 2
Pericardial effusion 5 6.0% 1 2
Pleural effusion 5 6.0% 1 2

Who Reports ALISERTIB Side Effects? Age & Gender Data

Gender: 60.0% female, 40.0% male. Average age: 50.7 years. Most reports from: US. View detailed demographics →

Is ALISERTIB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2012 1 1 1
2013 2 0 2
2014 3 1 2
2015 1 0 0
2016 6 1 3
2017 1 0 1

View full timeline →

What Is ALISERTIB Used For?

IndicationReports
Neuroblastoma 14
Pancreatic carcinoma 11
Neoplasm 8
Atypical teratoid/rhabdoid tumour of cns 7
Neoplasm malignant 6

Official FDA Label for ALISERTIB

Official prescribing information from the FDA-approved drug label.